WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that there will be four presentations at the upcoming 2012 American College of Clinical Oncology (ASCO) Annual Meeting on compounds that utilize the Company’s Targeted Antibody Payload (TAP) technology. Of particular note, the findings in the trastuzumab emtansine EMILIA Phase III trial will be featured in an ASCO plenary session on June 3, and findings with SAR3419 administered with its Phase II dosing schedule will be reported in a poster presentation on June 4, 2012. Trastuzumab emtansine and SAR3419 are in development by Roche and Sanofi, respectively, under agreements with ImmunoGen.
